REFERENCES
- Beck R W, Cleary P A, Anderson M M, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 326: 581–588, [PUBMED], [INFOTRIEVE], [CSA]
- Jacobs L D, Beck R E, Simon J H, Kinkel R P, Brownscheidle C M, Murray T J, et al. Intramuscular interferon beta 1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343(13)898–904, [INFOTRIEVE], [CROSSREF], [CSA]
- Comi G, Filippi E, Barkhoff F, et al. Effect of early interferon treatment on conversion to define multiple sclerosis: a randomized study. Lancet 2001; 357: 1576–1582, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Beck R W, Cleary P A, Trobe J D, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993; 329: 1764–1769, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Optic Neuritis Study Group. The 5 year risk of M.S. after optic neuritis: experience of the optic neuritis treatment trial. Neurology 1997; 49: 1404–1413, [CSA]
- Weinshenker B G, Bass B, Rice G P, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical cure and disability. Brain 1989; 112: 133–146, [INFOTRIEVE], [CSA]
- Ge Y, Grossman R I, Babb J S, He J, Mannon L J. Dirty-appearing white matter in multiple sclerosis; volumetric MR imaging and magnetization transfer ratio histogram analysis. Am J Neuroradiol 2003; 24(10)1935–1940, [PUBMED], [INFOTRIEVE], [CSA]
- Rudick R A, Fisher E, Lee J -C, Simon J, Jacobs L, Multiple Sclerosis Collaborative Research Group. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing remitting MS. Neurology 1999; 53: 1698–1704, [INFOTRIEVE], [CSA]
- Simon J H, Lull J, Jacobs L D, Rudick R A, Cookfair D L, Herndon R M, et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 2000; 55(2)185–192, [INFOTRIEVE], [CSA]
- Gone O, Catalaa I, Babb J S, et al. Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 2000; 54: 15–19, [CSA]
- Catalaa I, Grossman R, Kolson D L, et al. Multiple sclerosis: magnetization transfer histogram analysis of segmented normal-appearing white matter. Radiology 2000; 216: 351–355, [INFOTRIEVE], [CSA]
- Husted C A, Goodin D S, Hugg J W, Maudsley A A, Tsuruda J S, de Bie S H, et al. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 1994; 36(2)157–165, [INFOTRIEVE], [CROSSREF], [CSA]
- Goodkin D E, Rooney W D, Sloan R, Bacchetti P, Gee L, Vermathen M, et al. A serial study of new MS lesions and the white matter from which they arise. Neurology 1998; 51(6)1689–1697, [INFOTRIEVE], [CSA]
- Filippi M, Rocca M A, Martino G, Horsfield M A, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998; 43(6)809–814, [INFOTRIEVE], [CROSSREF], [CSA]
- Rocca M A, Mezzapesa D M, Falini A, et al. Evidence for axonal pathology and adaptive cortical reorganization with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage 2003; 18: 847–855, [INFOTRIEVE], [CROSSREF], [CSA]
- Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A, Martinelli V, Grossman R I, Scotti G, Comi G, Falini A. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003; 126(Pt 2)433–437, [INFOTRIEVE], [CROSSREF], [CSA]
- The once weekly interferon for MS Study Group (OWIMS). Evidence of interferon beta 1-A a dose response in relapsing-remitting MS. Neurology 1999; 53: 679–686, [CSA]
- Filippi M, Rovaris M, Barkhof F, et al. Brain volume changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis: results from the ETOMS study. J Neurol 2001; 248(Suppl 2)113, [CSA]
- Jones C K, Riddehough A, Li D KB, et al. MRI cerebral atrophy in relapsing-remitting MS: results from the PRISMS Trial. Neurology 2001; 56(Suppl 3)A379, [CSA]
- Trapp B D, Peterson J, Ransohoff R M, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338(5)278–285, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Trapp B D, Ranshoff R M, Fisher E, Rudick R A. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999; 5: 48–57, [CSA]
- Kendrick M, Johnson K I. Long-term treatment of multiple sclerosis with interferon-beta may be cost effective. Pharmacoeconomics 2000; 18: 45–53, [INFOTRIEVE], [CROSSREF], [CSA]
- Jacobs L D, Cookfair D L, Rudick R A, Herndon R M, Richert J R, Salazar A M, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39(3)285–294, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cohen J A, Cutter G R, Fischer J S, et al. Benefit of interferon B-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679–687, [INFOTRIEVE], [CSA]
- The PRISMS Study Group and the University of Bristish Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon B-1a in relapsing MS. Neurology 2001; 56: 1628–1636, [CSA]
- Schwid S R, Bever C T. The cost of delaying treatment in multiple sclerosis: what is lost is not regained. Neurology 2001; 56: 1620, [PUBMED], [INFOTRIEVE], [CSA]
- Johnson K P, Brooks B R, Ford C C, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Multiple Sclerosis 2000; 6: 255–266, [INFOTRIEVE], [CROSSREF], [CSA]
- The Champions Study Group. IM interferon beta 1-a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678–684, [CROSSREF], [CSA]
- Brex P A, Ciccarelli O, O'Riordan J I, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 156–164, [CROSSREF], [CSA]
- Hickman S, Dalton C, Miller D H, Plant G T. Management of acute optic neuritis. Lancet 2002; 360: 1953–1962, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Van d er, Worp H B, van Gijn J, Plant G T. Behandeling van neuritis optica. Ned Tijdschr Geneeskd 2004; 148: 61–65, [CSA]
- Hickman S J, Dalton C M, Miller D H, Π α π π α A, Plant G T. Management of acute optic neuritis. Greek Annals of Ophthalmology 2004; 4: 325–348, [CSA]
- Kapoor R, Miller D H, Jones S J, Plant G T, Brusa A, Gass A, Hawkins C P, Page R, Wood N W, Compston D A, Moseley I F, McDonald W I. Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology 1998; 50(1)230–237, [PUBMED], [INFOTRIEVE], [CSA]
- Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a metanalysis of randomized controlled clinical trials. J Neurol. 2000; 247: 435–442, [INFOTRIEVE], [CROSSREF], [CSA]
- http://www.update-software.com/Abstracts/EYESAbstractIndex.htm
- McAlpine D, Lumsden C E, Acheson E D. Multiple sclerosis. A reappraisal. E and S Livingstone Ltd., London 1965; 185
- Beck R W, Smith C H, Gal R L, Xing D, Bhatti M T, Brodsky M C, Buckley E G, Chrousos G A, Corbett J, Eggenberger E, Goodwin J A, Katz B, Kaufman D I, Keltner J L, Kupersmith M J, Miller N R, Moke P S, Nazarian S, Orengo-Nania S, Savino P J, Shults W T, Trobe J D, Wall M, Optic Neuritis Study Group. Neurologic impairment 10 years after optic neuritis. Arch Neurol 2004; 61(9)1386–1389, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- http://www.theabn.org/downloads/msdoc.pdf
- Ebers G C. Preventing multiple sclerosis?. Lancet 2001; 357: 1547, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pittock S J, Mayr W T, McClelland R D, et al. Change in MS-related disability in a population-based cohort 10-year follow-up study. Neurology 2004; 62(1)51–59, [INFOTRIEVE], [CSA]
- McDonald W I, Compston A, Edan G, Goodkin D, Hartung H P, Lublin F D, McFarland H F, Paty D W, Polman C H, Reingold S C, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker B Y, Wolinsky J S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50(1)121–127, [INFOTRIEVE], [CROSSREF], [CSA]
- Swanton J K, Fernando K T, Dalton C M, Miszkiel K A, Thompson A J, Plant G T, Miller D H. Modification of MRI criteria for MS in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2005, In press[CSA]
- Jacobs L D, Beck R E, Simon J H, Kinkel R P, Brownscheidle C M, Murray T J, et al. Intramuscular interferon beta 1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343(13)898–904, [INFOTRIEVE], [CROSSREF], [CSA]
- Jacobs L D, Cookfair D L, Rudick R A, Herndon R M, Richert J R, Salazar A M, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39(3)285–294, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Optic Neuritis Study Group. High risk and low risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 2003; 121: 944–949, [CROSSREF], [CSA]
- McFarland H F, Stone L A, Calabresi P A, et al. MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring the effectiveness of experimental therapies. Multiple Sclerosis 1996; 2: 198–205, [INFOTRIEVE], [CSA]
- Rudick R A. Evolving concepts in the pathogenesis of multiple sclerosis and their therapeutic implications. J Neuro-Ophthalmol 2001; 21: 279–283, [CROSSREF], [CSA]
- Brex P A, Ciccarelli O, O'Riordan J I, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158–164, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McDonald I W, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121–127, [INFOTRIEVE], [CROSSREF], [CSA]
- Catalaa I, Grossman R, Kolson D L, et al. Multiple sclerosis: magnetization transfer histogram analysis of segmented normal-appearing white matter. Radiology 2000; 216: 315–355, [CSA]
- Gone O, Catalaa I, Babb J S, et al. Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 2000; 54: 15–19, [CSA]
- Law M, Saindane A M, Ge Y, et al. Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology 2004; 231: 645–652, [INFOTRIEVE], [CSA]
- Ge Y, Law M, Johnson G, et al. Preferential occult injury of corpus callosum in multiple sclerosis measured by diffusion tensor imaging. J Magn Reson Imaging 2004; 20: 1–7, [INFOTRIEVE], [CROSSREF], [CSA]
- Santos A C, Narayanan S, DeStefano N, et al. Magnetization transfer can predict clinical evolution in patients with multiple sclerosis. J Neurol 2002; 249: 662–668, [INFOTRIEVE], [CSA]
- DeStefano N, Nicola M D, Narayanan S, et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 2002; 59: 1565–1571, [CSA]
- Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multiple sclerosis is extensive in early disease stages and decreases over time. Brain 2002; 125: 2202–2212, [INFOTRIEVE], [CROSSREF], [CSA]
- Fisher E, Rudick R, Simon J H, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412–1420, [INFOTRIEVE], [CSA]
- Rudick R A. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis. J Neuroimaging 2004; 14(3 Suppl.)54S–64S, [INFOTRIEVE], [CROSSREF], [CSA]
- Hardmeier M, Wagenpfeil S, Freitag P, et al. Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis. Arch Neurol 2003; 60: 1736–1739, [INFOTRIEVE], [CROSSREF], [CSA]
- DeStefano N, Matthews P M, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003; 60: 1157–1162, [CSA]
- Simon J H. Brain and spinal cord atrophy in multiple sclerosis: role as a surrogate measure of disease progression. CNS Drugs 2001; 15: 427–436, [INFOTRIEVE], [CROSSREF], [CSA]
- Paolillo A, Piatella M C, Dilegge S, et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DPTA. J Neurol 2004; 251: 432–439, [INFOTRIEVE], [CROSSREF], [CSA]
- Fischer J S, Priore R L, Jacobs L D, et al. Neuropsychological effects of interferon B-1a in relapsing multiple sclerosis. Ann Neurol 2000; 6: 885–892, [CROSSREF], [CSA]
- Lyon-Caen O, Jouvent R, Hauser S, et al. Cognitive function in recent-onset demyelinating diseases. Arch Neurol 1986; 43: 1138–1141, [INFOTRIEVE], [CSA]
- Balcer L J, Baier M L, Cohen J A, et al. Contrast letter acuity as a visual component for the multiple sclerosis functional composite. Neurology 2003; 61: 1367–1373, [INFOTRIEVE], [CSA]
- Siu-Ling M A, Shea J, Galetta S L, et al. Self-reported visual dysfunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionaire. Am J Ophthalmol 2002; 133: 686–692, [CROSSREF], [CSA]
- Arnoldus J HA, Killestein J, Pfennings L, et al. Quality of life during the first 6 months of interferon-B treatment in patients with MS. Multiple Sclerosis 2000; 6: 338–342, [INFOTRIEVE], [CROSSREF], [CSA]
- Cohen J A, Cutter G R, Fischer J S, et al. Benefit of interferon B-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679–687, [INFOTRIEVE], [CSA]
- Beck R W, Chandler D L, Cole S R, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS Trial subgroup analyses. Ann Neurol 2002; 51: 481–490, [INFOTRIEVE], [CROSSREF], [CSA]
- Beck R W, Chandler D L, Cole S R, et al. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002; 59: 998–1005, [CSA]
- Tintore M, Rovira A, Rio J, et al. Is optic neuritis more benign than other first attacks in multiple sclerosis?. Ann Neurol 2005; 57: 210–215, [INFOTRIEVE], [CROSSREF], [CSA]
- Toole J F. Surgery for carotid artery stenosis. Br Med J 2004; 329: 635–636, [CSA]